Eli Lilly and Company
New York Stock ExchangeTotal Valuation
Eli Lilly and Company carries a market capitalization of 1.08T, placing it among publicly traded companies globally. Its enterprise value stands at 1.12T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.08T |
| Enterprise Value | 1.12T |
Share Statistics
Eli Lilly and Company currently has 891.50M shares outstanding.
| Shares Outstanding | 891.50M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Eli Lilly and Company trades at a trailing price-to-earnings ratio of 40.15. The price-to-sales ratio is 13.46, and the price-to-book ratio stands at 31.56.
| PE Ratio | 40.15 |
| PS Ratio | 13.46 |
| PB Ratio | 31.56 |
| P/TBV Ratio | 154.52 |
| P/FCF Ratio | 25.24 |
| P/OCF Ratio | 38.19 |
Enterprise Valuation
On an enterprise value basis, Eli Lilly and Company trades at an EV/EBITDA multiple of 26.74 and an EV/FCF ratio of 26.09. The EV/Sales ratio of 14.00 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 28.16 provides insight into valuation relative to core operating earnings.
| EV / Sales | 14.00 |
| EV / EBITDA | 26.74 |
| EV / EBIT | 28.16 |
| EV / FCF | 26.09 |
Financial Position
Eli Lilly and Company maintains a current ratio of 1.35, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 162.07, indicating elevated leverage, while an interest coverage ratio of 232.22 demonstrates strong ability to service its debt obligations.
| Current Ratio | 1.35 |
| Quick Ratio | 0.68 |
| Debt / Equity | 162.07 |
| Debt / EBITDA | 1.32 |
| Interest Coverage | 232.22 |
Financial Efficiency
Eli Lilly and Company posts a return on equity of 102.44 and a return on invested capital of 40.90.
| Return on Equity (ROE) | 102.44 |
| Return on Assets (ROA) | 21.97 |
| Return on Invested Capital (ROIC) | 40.90 |
| Return on Capital Employed (ROCE) | 36.53 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.95 |
Taxes
Over the trailing twelve months, Eli Lilly and Company has paid 6.88B in income taxes, reflecting an effective tax rate of 20.49.
| Income Tax | 6.88B |
| Effective Tax Rate | 20.49 |
Stock Price Statistics
Eli Lilly and Company's stock has gained approximately 54.55439% over the past 52 weeks. The 50-day moving average sits at 1,191.07, while the 200-day moving average is 1,062.69.
| Beta (5Y) | N/A |
| 52-Week Price Change | 54.55439% |
| 50-Day Moving Average | 1,191.07 |
| 200-Day Moving Average | 1,062.69 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Eli Lilly and Company generated 79.67B in revenue and converted that into 26.71B in net income, yielding earnings per share of 29.79. EBITDA reached 41.71B, while operating income came in at 39.61B.
| Revenue | 79.67B |
| Gross Profit | 66.44B |
| Operating Income | 39.61B |
| Pretax Income | 33.60B |
| Net Income | 26.71B |
| EBITDA | 41.71B |
| EBIT | 39.61B |
| Earnings Per Share (EPS) | 29.79 |
Balance Sheet
Eli Lilly and Company holds 8.95B in cash and equivalents against 54.91B in total debt, resulting in a net debt position of 45.96B. Total book value stands at 33.88B, with working capital of 16.93B providing operational flexibility.
| Cash & Cash Equivalents | 8.95B |
| Total Debt | 54.91B |
| Net Debt | 45.96B |
| Equity (Book Value) | 33.88B |
| Book Value Per Share | 38.00 |
| Working Capital | 16.93B |
Cash Flow
Eli Lilly and Company produced 28.08B in operating cash flow over the past twelve months. After subtracting -14.52B in capital expenditures, free cash flow totaled 13.56B - equivalent to 15.16 per share.
| Operating Cash Flow | 28.08B |
| Capital Expenditures | -14.52B |
| Free Cash Flow | 13.56B |
| FCF Per Share | 15.16 |
Margins
Eli Lilly and Company operates with a gross margin of 83.40, reflecting its pricing power and cost economics. The operating margin of 49.72 and net profit margin of 33.53 provide insight into operational efficiency.
| Gross Margin | 83.40 |
| Operating Margin | 49.72 |
| Pretax Margin | 42.17 |
| Profit Margin | 33.53 |
| EBITDA Margin | 52.35 |
Dividends & Yields
The company's payout ratio of 21.66 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 6.47 |
| Dividend Yield | N/A |
| Payout Ratio | 21.66 |
| Shareholder Yield | -0.24 |
| FCF Yield | 3.96 |
Stock Splits
Eli Lilly and Company's most recent stock split took place on October 16, 1997 with a 1:2 split ratio.
| Last Split Date | 10/16/1997 |
| Split Ratio | 1:2 |
Scores
Eli Lilly and Company posts an Altman Z-Score of 8.31, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 8.31 |